Clinical Trial

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09-30 -> 2029-09-30 2026-08-14
minor Completion pushed: 2027-02-28 -> 2030-08 2026-08-14
Trial Details
NCT Number NCT06416410
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
Enrollment 392 participants
Start Date 2024-08-07
Primary Completion 2029-09-30 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-13